Tradestie Institutional Equity Comparison Engine

VIVS vs MRNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MRNA Overall Edge

MRNA Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VIVS trades at N/M Forward P/E with -10117.0% operating margin (-51.4% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, VIVS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (61st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
VIVS N/M vs MRNA 23.0x Fwd P/E
Growth & Margin Winner MRNA
Op Margin -10117.0% vs -80.8% ยท YoY -51.4% vs +29.2%
Momentum & Technical Winner MRNA
1Y -87.0% vs +699.9% ยท 52W Pos 5% vs 68%
Options & Structure Winner MRNA
BREAKDOWN (N/A IV) vs CONSOLIDATION (61st %ile IV)
VIVS NASDAQ
VivoSim Labs, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.29
+142.92% 1D
Market Cap $2.4M
1M Return +64.69%
1Y Return -86.99%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 5.0 Fund 38.0 Flow 50.0 Mom 50.0
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$199.33
+1.29% 1D
Market Cap $79.6B
1M Return -18.91%
1Y Return +699.88%
Forward P/E 23.0x
Unified AI Score
39.5 / 100 SELL
Tech 15.0 Fund 42.0 Flow 68.0 Mom 46.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VIVS -86.99% MRNA +699.88% Spread: +786.87 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period VIVS Revenue MRNA Revenue VIVS Op. Margin MRNA Op. Margin Margin Edge
FY2019 $0M $60M -882.4% -906.8% VIVS
FY2020 $0M $800M -977.9% -95.0% MRNA
FY2021 N/A $18.5B N/A 72.0% MRNA
FY2022 $0M $19.3B -765.3% 48.9% MRNA
FY2023 $0M $6.85B -4792.2% -61.9% MRNA
FY2024 $0M $3.24B -13840.4% -121.9% MRNA
FY2025 $0M $1.94B -8761.1% -158.1% MRNA
FY2026 $0M N/A -8768.7% N/A VIVS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VIVS (1) vs MRNA (9)
Institutional Metric VIVS MRNA Criterion Row Winner
Market Capitalization Scale $2.4M $79.6B Larger Scale MRNA
Trailing P/E Ratio Valuation N/M 23.0x Lower Multiple MRNA
Forward P/E Ratio Valuation N/M 23.0x Lower Multiple MRNA
Revenue Growth (YoY) Growth -51.4% +29.2% Higher Growth MRNA
Operating Margin (TTM) Profitability -10117.0% -80.8% Higher Margin MRNA
Net Profit Margin Profitability 0.0% -110.5% Higher Margin VIVS
Return on Equity (ROE) Capital Efficiency -343.1% -34.5% Higher ROE MRNA
52-Week Range Position Momentum 5% ($0โ€“$3) 68% ($22โ€“$281) Stronger Trend MRNA
Beta / 30D Volatility Risk Regime 0.83ฮฒ ยท 480% Vol 2.31ฮฒ ยท 97% Vol Lower Realized Risk MRNA
Unified Institutional Score Composite Signal 36.8 / 100 (SELL) 39.5 / 100 (SELL) Higher Composite MRNA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VIVS vs MRNA Buy Guide
VIVS BREAKDOWN
73d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live VIVS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
21d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 61st %ile
IV Regime Elevated (60thโ€“80th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VIVS nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.